question: What is the associated phenotype for the SLCO1B1 *1/*5 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*8 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*6 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*26 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*5 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*14 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*44 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*7 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*29 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*10 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*41 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*37 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*28 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*43 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*19 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*30 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has a SLCO1B1 *1/*10 diplotype. What is the phenotype for this diplotype?
retrieved_docs: [Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*10 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*10 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*11 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*11 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*2 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*14 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*19 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient's PGx result indicates CYP2C9 *2 *6 diplotype. Does this mean she is a poor metabolizer?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *6/*26  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*23  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*28  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*8  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*29  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*12  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*16  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*11  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*44  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*30  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*38  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*14  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What is the  phenotype for  SLCO1B1 *6/*31 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *6/*6 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*36 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*26 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*14 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*11 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*13 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*19 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has the ABCG2 rs2231142 reference on both alleles. is this mean she has normal function?
retrieved_docs: [Document(page_content="\ufeffPatients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 reference (G)' display ABCG2 Normal Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are some diplotypes for SLCO1B1 Increased Function impacting statins?
retrieved_docs: [Document(page_content='16 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S1.  EVIDENCE LINKING SLCO1B1 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References Level of Evidence Atorvastatin In vitro SLCO1B1 is the major atorvastatin uptake transporter.  The average contribution to atorvastatin uptake was SLCO1B1 > SLCO1B3 >> OATP2B1 > NTCP. Vildhede, et al. (2014) (83) Weak In vitro  SLCO1B1 rs4149056 (c.521T>C, *5) reduces atorvastatin transport activity by decreasing OATP1B1 function due to sorting errors in transporter localization Kameyama, et al. (2005) (84) Weak Clinical SLCO1B1 rs4149056 (c.521T>C) C allele is associated with an increased risk of atorvastatin-induced myopathy. Puccetti, et al. (2010) (85) Brunham, et al. (2012) (86) Santos, et al. (2012) (87) Hou, et al. (2015) (88) Hubacek, et al. (2015) (89) Mirosevic, et al. (2015) (90) Liu, et al. (2017) (91) Xiang, et al. (2018) (92) Du, et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='14 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0   FIGURE S1. PHARMACOKINETIC IMPACT OF RS4149056 GENOTYPE FOR SEVERAL STATINS.  Effect of the SLCO1B1 c.521T>C variant (rs4149056) on plasma exposure (i.e., area under the concentration-time curve) for different statins, CC vs TT. This summary figure represents a composite of single-dose data from the following references: Pasanen et al (4), Ieiri et al (18), Lee et al. (77), Niemi et al (78), Pasanen et al (79), Choi et al (80), Deng et al (17), Ho et al (81).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='18 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Du, et al. (2018) (93) Fluvastatin Clinical Presence of the SLCO1B1*14 allele is associated with enhanced lipid-lowering efficacy for fluvastatin. Couvert, et al. (2008) (115) Moderate Clinical The SLCO1B1 rs4149056 (c.521T>C) C variant is associated with decreased lipid- lowering response to fluvastatin. Couvert, et al. (2008) (115) Meyer, et al. (2015) (110) Xiang, et al. (2018) (116) Weak In vitro The uptake of fluvastatin was not influenced by SLCO1B1 rs4149056 (c.521T>C) at concentrations >1 uM Deng, et al. (2008) (117) Xiang, et al. (2020 (118) Moderate In vitro The SLCO1B1 rs4149056 (c.521T>C) C variant is associated with reduced uptake of both fluvastatin enantiomers (3R,5S-fluvastatin and 3S,5R-fluvastatin). Hirvensalo, et al. (2019) (119) Moderate Clinical Fluvastatin PK did not differ between subjects with different SLCO1B1 rs4149056 (c.521T>C) genotypes. Niemi, et al. (2006) (120) Zhou, et al.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020SLCO1B1 521TC: simvastatine4055When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='17 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Clinical  SLCO1B1 rs4149056 (c.521T>C) C polymorphism affects the pharmacokinetics of atorvastatin (higher AUC and Cmax). Pasanen, et al. (2007) (79) Lee, et al. (2010) (99) DeGorter, et al. (2013) (22) Daka, et al. (2015) (100) Birmingham, et al. (2015) (101) Leon-Cachon, et al. (2016) (102) Rajput, et al. (2017) (103) Wang, et al. (2017) (104) Woo, et al. (2017) (105) Lee, et al. (2019) (106) Mori, et al. (2019) (95) Turner, et al. (2020) (97) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='atorvastatin,,,,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,No CDS,n/a', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='test information by providers and is available at http://www.ncbi.nlm.nih.gov/gtr/.   LINKING GENETIC VARIABILITY TO VARIABILITY IN DRUG-RELATED PHENOTYPES  SLCO1B1. Both SLCO1B1 decreased and poor function phenotypes are associated with increased exposure for most statins, with greater effects of poor function phenotypes.  Effects on exposure also vary by statin type (Figure S1). Therefore, the risk of SAMS varies based on statin type and statin dose. For simvastatin, the evidence linking SAMS to SLCO1B1 rs4149056 (c.521T>C) is of high quality, and this association has been reproduced in retrospective studies of randomized trials and clinical practice-based cohorts (Table S1). This variant is present in several SLCO1B1 star alleles including the relatively common SLCO1B1*5 and *15 alleles. Although the association of rs4149056 with myopathy varies by statin, there is evidence supporting the role of SLCO1B1 variants in the systemic clearance of all statins (3) (Table S1).  Pasanen et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 38  (111) Prado, Y., Saavedra, N., Zambrano, T., Lagos, J., Rosales, A. & Salazar, L.A. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci  16, 20609-19 (2015). (112) Mladenovska, K. et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie  72, 288-95 (2017). (113) de Keyser, C.E. et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics  24, 43-51 (2014). (114) Kadam, P., Ashavaid, T.F., Ponde, C.K. & Rajani, R.M. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther  41, 329-33 (2016). (115) Couvert, P. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='20 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Birmingham, et al. (2015) (101) Choi, et al. (2015) (142)  Luzum, et al. (2015) (143) Hasunuma, et al. (2016) (144) Jiang, et al. (2017) (145) Wagner, et al. (2018) (146) Ogungbenro, et al. (2019) (147)  Clinical Individuals with the SLCO1B1 rs4149056 (c.521T>C) C allele showed an attenuated lipid-lowering effect compared with those homozygous for the 521T allele. The effect size may be small. Tachibana-Iimori, et al. (2004) (107) Bailey, et al. (2010) (148) Hopewell, et al. (2013) (149) Giannakopoulou, et al. (2014) (109) Dou, et al. (2015) (150) Li, et al. (2015) (151) Meyer, et al. (2015) (110) Kitzmiller, et al. (2017) (152) Oni-Orisan, et al. (2018) (153) Kaewboonlert, et al. (2018) (154) Wu, et al. (2018) (155) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020CYP2C9 *1/*2: siponimod7160NO action is required for this gene-drug interaction.The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects.Literature:1. Gardin A et al. Siponimod', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: A SLCO1B1 *1/*20 diplotype would have which phenotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *19/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*26 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*36 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *16/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Wht phenotype is associated with SLCO1B1 *14/*14 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *14/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*26 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*19 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*36 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What is the associated phenotype for the CYP2C9 *2/*15 diplotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*15  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*15  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*14  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*14  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*55  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *14/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: List SLCO1B1 diplotypes with a normal function phenotype.
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*14 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has ABCG2 decreased function. Can you tell me what variant he has?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*23 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has rs2231142 variant (T) in the  ABCG2 gene. What is her phenotype?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='facilitates the export of compounds into the extracellular space. \nThe ABCG2  gene locus spans over 66\xa0kb on chromosome 4 (Chr \n4q22.1). The common variant p.Q141K (c.421C>A, rs2231142) \nhas been studied extensively; the minor A allele is associated \nwith 30–  40% reduced protein expression compared with the \nreference allele and with increased plasma levels of rosuvastatin \n(Table\xa0 S2) (ABCG2  Allele  Definition Table and ABCG2  \nAllele  Functionality Table6,7). Differences in allele frequencies \nhave been observed across multiple geographically, racially, and \nethnically diverse groups ( ABCG2  Allele Frequency Table6,7).\nCYP2C9.  The cytochrome P450 2C9 (CYP2C9) enzyme \ncontributes to the phase I metabolism of many drugs. CYP2C9  \nis one of the CYP2C  genes clustered in a 500-  kb region on 10q24 \n(Chr 10q23.33). The CYP2C9  gene is highly polymorphic, with \nat least 71 variant alleles ( CYP2C9 Allele Definition Table6,7,9).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='22 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S2.  EVIDENCE LINKING ABCG2 GENOTYPE WITH STATIN PHENOTYPE Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical ABCG2 rs2231142 (c.421C>A) CA genotype is found to be more frequent in statin-intolerant cases. Shek, et al. (2017) (134)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is associated with simvastatin-induced liver symptoms. Shek, et al. (2018) (162)  Moderate  Clinical ABCG2 rs2231142 (c.421C>A) may be associated with statin-induced muscle symptoms. Chan, et al. (2019) (139) Weak Clinical ABCG2 rs2231142 (c.421C>A) A allele carriers had higher AUC(0-t) and Cmax of simvastatin acid as compared with those carrying the CC genotype. It did not affect simvastatin lactone concentration. Keskitalo, et al. (2009) (163) Birmingham, et al. (2015) (101) Choi, et al. (2015) (142)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is not', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My test results show rs2231142 variant and reference on ABCG2 gene. What does this mean?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My genetic test result shows CYP2C9 *12 *38 diplotype. What is the meaning of this?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *38/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *12/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*55  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*50  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *14/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *29/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *28/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *12/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *11/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What are the genotypes for CYP2C9 Normal Metabolizer impacting statins?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *16/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*24  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*25  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*8  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*16  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *15/*16  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *24/*28  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *13/*16  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*28  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *4/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*14  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *14/*24  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *14/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My patient has *1/*7 diplotype in the CYP2C9 gene. Does this have a known phenotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *1/*7  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*27  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*67  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*17  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*72  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*27  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*7  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*6  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*73  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*57  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*28  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*71  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*18  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*19  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*17  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*47  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*14  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*3  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My patient has *3/*31 diplotype in the CYP2C9 gene. What is the phenotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *3/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*30  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*29  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*26  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*23  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*28  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*3  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*11  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*16  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*38  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*14  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*4  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*8  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*39  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What phenotype is associated with the SLCO1B1 *1/*37 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *37/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*38 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *36/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *32/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *19/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *33/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Can you tell me the phenotype for the CYP2C9 *1/*3 diplotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *3/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*3  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*6  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*39  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*39  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*43  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*43  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*45  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*15  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*11  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What is the phenotype for the SLCO1B1 *14/*20 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*14 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *13/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *16/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*19 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient's PGx result indicates CYP2C9 *1/*6 diplotype. What does this mean?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *6/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*6  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *46/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What phenotype is associated with the ABCG2 rs2231142 variant on both alleles?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='facilitates the export of compounds into the extracellular space. \nThe ABCG2  gene locus spans over 66\xa0kb on chromosome 4 (Chr \n4q22.1). The common variant p.Q141K (c.421C>A, rs2231142) \nhas been studied extensively; the minor A allele is associated \nwith 30–  40% reduced protein expression compared with the \nreference allele and with increased plasma levels of rosuvastatin \n(Table\xa0 S2) (ABCG2  Allele  Definition Table and ABCG2  \nAllele  Functionality Table6,7). Differences in allele frequencies \nhave been observed across multiple geographically, racially, and \nethnically diverse groups ( ABCG2  Allele Frequency Table6,7).\nCYP2C9.  The cytochrome P450 2C9 (CYP2C9) enzyme \ncontributes to the phase I metabolism of many drugs. CYP2C9  \nis one of the CYP2C  genes clustered in a 500-  kb region on 10q24 \n(Chr 10q23.33). The CYP2C9  gene is highly polymorphic, with \nat least 71 variant alleles ( CYP2C9 Allele Definition Table6,7,9).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Clinical ABCG2 rs2231142 (c.421C>A) A allele is not significantly associated with an increased risk of atorvastatin-induced liver tox. Fukunaga, et al. (2016) (98) Weak Clinical ABCG2 rs2231142 (c.421C>A) A allele is significantly associated with an increased risk of atorvastatin-induced adverse events. Mirosevic Skvrce, et al. (2015) (90) Moderate', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='22 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S2.  EVIDENCE LINKING ABCG2 GENOTYPE WITH STATIN PHENOTYPE Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical ABCG2 rs2231142 (c.421C>A) CA genotype is found to be more frequent in statin-intolerant cases. Shek, et al. (2017) (134)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is associated with simvastatin-induced liver symptoms. Shek, et al. (2018) (162)  Moderate  Clinical ABCG2 rs2231142 (c.421C>A) may be associated with statin-induced muscle symptoms. Chan, et al. (2019) (139) Weak Clinical ABCG2 rs2231142 (c.421C>A) A allele carriers had higher AUC(0-t) and Cmax of simvastatin acid as compared with those carrying the CC genotype. It did not affect simvastatin lactone concentration. Keskitalo, et al. (2009) (163) Birmingham, et al. (2015) (101) Choi, et al. (2015) (142)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is not', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='8 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  to higher allele frequencies of the reduced function ABCG2 polymorphism, c.421G>A (rs2231142) (25); however, other factors may contribute to higher rosuvastatin levels in Asians (26). The effect of the ABCG2 polymorphism, rs2231142 (c.421C>A), has also been studied for its association with pharmacokinetic, toxicity or efficacy with other statins, such as atorvastatin, pitavastatin, fluvastatin and lovastatin (Table S2).  Except for fluvastatin, in which a single study showed a clear association of rs2231142 with exposure, the evidence for association of ABCG2 genetic variants with exposure, response or toxicity to other statins is considered weak to moderate primarily because of small sample sizes or variation in results among studies (Table S2).   CYP2C9. Genetic variations in CYP2C9 are associated with increased exposure to fluvastatin (Table S3), but the pharmacokinetics or pharmacodynamics of other statins', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='23 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Lee, et al. (2013) (168) Kim, et al. (2017) (169) Kim, et al. (2019) (170) Clinical ABCG2 SNP rs2199936 is significantly associated with absolute LDL-C reduction. (rs2231142 (421C>A) is in LD with rs2199936 in the HapMap (CEU, r2=0.81)). Chasman, et al. (2012) (171)  High  Clinical ABCG2 rs2231142 (c.421C>A) is significantly associated with rosuvastatin exposure. Genotypes AC + AA are associated with increased exposure to rosuvastatin compared to CC. Zhang, et al. (2006) (172) Keskitalo, et al. (2009) (21) Zhou, et al. (2013) (173) DeGorter, et al. (2013) (22) Lee, et al. (2013) (168) Birmingham, et al. (2015) (174) Birmingham, et al. (2015) (101) Wan, et al. (2015) (175) Kim, et al. (2019) (170) Liu, et al. (2016) (176) Kashihara, et al. (2017) (177) Bai, et al. (2019) (23) Soko, et al. (2019) (178) Zhang, et al. (2020) (179) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical In vitro study showed that ABCG2 affect atorvastatin transport. Keskitalo, et al. (2009) (21) High   Clinical ABCG2 rs2231142 (c.421C>A) is not associated with atorvastatin response. Prado, et al. (2018) (181) Moderate Clinical ABCG2 rs2231142 (c.421C>A) is not associated with decreased clearance of pravastatin. Ho, et al. (2007) (182) Keskitalo, et al. (2009) (163) Lu, et al. (2016) (183) Moderate In vitro Pitavastatin acid is a substrate of ABCG2, whereas the lactone form is not. ABCG2 is involved in the biliary excretion of pitavastatin. Fujino, et al. (2005) (184) Hirano, et al. (2005) (185) Moderate Clinical ABCG2 rs2231142 (c.421C>A) is not significantly associated with concentration of pitavastatin. Ieiri, et al. (2007) (127) Oh, et al. (2013) (128) Moderate Clinical ABCG2 rs2231142 (c.421C>A) AA genotype is associated with higher fluvastatin AUC. Keskitalo, et al. (2009) (163) High Clinical ABCG2 rs2231142 (c.421C>A) is associated with greater odds of developing', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. Pharmacogenomics J  19, 240-8 (2019). (179) Zhang, D. et al. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. Eur J Clin Pharmacol  76, 939-46 (2020). (180) Tsamandouras, N., Guo, Y., Wendling, T., Hall, S., Galetin, A. & Aarons, L. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Pharmacogenet Genomics  27, 27-38 (2017). (181) Prado, Y., Zambrano, T. & Salazar, L.A. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. J Clin Pharm Ther  43, 87-91 (2018). (182) Ho, R.H. et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics  17, 647-56 (2007).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's test results show *12/*23 on SLCOB1. What does this mean?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *12/*12 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*13 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*26 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*14 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*19 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does SLCO1B1 *1 *1 mean?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*48 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*49 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*33 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*41 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My PGx test results say that I have CYP2C9 *2 / *13 genotype, before I meet with my doctor, I would like to get more information on this.
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*12  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*11  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*23  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*14  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*28  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*43  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What are the implications of having a *2/*33 diplotype in the gene CYP2C9?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *23/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*44  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*38  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*23  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*55  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *30/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What are therapy implications for a patient with SLCO1B1 *11/*46 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *11/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *11/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *13/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *41/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *43/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *13/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *45/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *45/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *40/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *11/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *11/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *11/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does CYP2C9 *1/*9 mean?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *9/*39  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*45  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*42  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*25  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*43  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*52  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*15  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*28  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*24  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*11  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*23  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*35  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My genetic test results indicate that I might be at risk of muscle pain if I take some cholesterol medications because I have SLCO1B1 *1/*9 diplotype. I would like to understand this better.
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *9/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*16 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*26 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*13 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*33 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*41 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*28 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*24 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *13/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*30 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *16/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*45 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*10 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has a SLCO1B1 *2/*31 diplotype. What are therapeutic implications?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*23 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*32 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *32/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *32/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*34 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*44 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*33 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*41 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What are CPIC guidelines for SLCO1B1 *1/*14 genotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *14/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*38 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*36 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*26 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *11/*14 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Are there any therapeutic guidelines for CYP2C9 *1 *2 diplotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *1/*9  display a CYP2C9 Normal Metabolizer phenotype with an activity score of 2.0. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*2  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*3  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*11  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*8  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*12  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*12  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*4  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*11  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='\ufeffPatients with the CYP2C9 Diplotype *1/*1  display a CYP2C9 Normal Metabolizer phenotype with an activity score of 2.0. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*9  display a CYP2C9 Normal Metabolizer phenotype with an activity score of 2.0. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*2  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What does having alleles *4/*44 in the SLCO1B1 gene mean?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *4/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*4 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What is the metabolizer phenotype for CYP2C9 *2/*45 genotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *45/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*50  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*55  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *44/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *14/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*55  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*44  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *46/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *35/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *43/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What does CYP2C9 *4 *61 do?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *43/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *39/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *52/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *24/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *35/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *15/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *13/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *44/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *4/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *4/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *4/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *44/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What is the EHR notation for SLCO1B1 *49/*49?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *39/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *43/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *41/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *41/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does a CYP2C9 *3/*5 diplotype indicate?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *5/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*5  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*23  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*30  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*55  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *5/*5  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*5  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *5/*23  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *5/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *5/*30  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*23  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *5/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*30  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*12  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*11  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My patient's genetic test shows SLCO1B1 *27/*49. What gene is this associated with?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *27/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *23/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *29/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *25/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*49 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *24/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *29/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Can you explain the SLCO1B1 *34/*42 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *34/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *33/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *38/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *32/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *36/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*38 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *40/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*36 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My genetic test indicates a CYP2C9 *2/*8 genotype. What gene is this related to?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*8  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*8  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*28  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*28  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*28  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *28/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: Is there any difference between SLCO1B1 decreased function and SLCO1B1 possible decreased function for simvastatin dosage?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='with normal function \nand decreased function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe ≤20\xa0mg as a starting dose and adjust \ndoses of rosuvastatin based on disease-  specific \nand population-  specific guidelines If dose >20\xa0mg \nneeded for desired efficacy, consider combination \ntherapy (i.e., rosuvastatin plus nonstatin guideline-  \ndirected medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSimvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased simvastatin \nacid exposure as \ncompared with normal \nfunction; increased risk \nof myopathyPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If simvastatin therapy is', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: How does SLCO1B1 decreased function affect simvastatin dosage?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='with normal function \nand decreased function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe ≤20\xa0mg as a starting dose and adjust \ndoses of rosuvastatin based on disease-  specific \nand population-  specific guidelines If dose >20\xa0mg \nneeded for desired efficacy, consider combination \ntherapy (i.e., rosuvastatin plus nonstatin guideline-  \ndirected medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSimvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased simvastatin \nacid exposure as \ncompared with normal \nfunction; increased risk \nof myopathyPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If simvastatin therapy is', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='leads to reduced simvastatin transport to the liver, which increases the simvastatin plasma concentration and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39%and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option:1. Avoid simvastatin doses', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: Will my patient's genetic status for the SLCO1B1 gene affect their atorvastatin prescription?
retrieved_docs: [Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='leads to reduced simvastatin transport to the liver, which increases the simvastatin plasma concentration and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='T.A., Naveed, A.K., Farooqi, Z.R. & Khan, S. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin. Pak J Pharm Sci  30, 1363-70 (2017). (104) Wang, Y. et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie  72, 365-8 (2017). (105) Woo, H.I., Kim, S.R., Huh, W., Ko, J.W. & Lee, S.Y. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Des Devel Ther  11, 1135-46 (2017). (106) Lee, N. et al. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug Metab Pharmacokinet  34, 387-95 (2019). (107) Tachibana-Iimori, R. et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet  19, 375-80 (2004).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.8. Fu Q et al. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020SLCO1B1 521TC: fluvastatine4059NO action is required for this gene-drug interaction.The gene variation increases the plasma concentration of fluvastatin, but there is insufficient evidence to prove an effect on efficacy or side effects.Literature:1. Hirvensalo P et al. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther 2019;106:668-80.2. Mori D et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019;34:78-86.3. Xiang Q et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics 2018;28:261-7.4. Meyer zu Schwabedissen HE et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='liver injury in Japanese population. BMC Genet  17, 79 (2016). (99) Lee, Y.J., Lee, M.G., Lim, L.A., Jang, S.B. & Chung, J.Y. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther  48, 36-45 (2010). (100) Daka, A. et al. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. Pharmazie  70, 480-8 (2015). (101) Birmingham, B.K. et al. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol  71, 341-55 (2015). (102) Leon-Cachon, R.B.R. et al. A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers. BMC Cancer  16, 74 (2016). (103) Rajput, T.A., Naveed, A.K., Farooqi, Z.R. & Khan, S.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39%and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option:1. Avoid simvastatin doses', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.20. Pasanen MK et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33.21. Hermann M et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006;79:532-9.22. Thompson JF et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020NUDT15 IM: azathioprine/mercaptopurine7035Grade ≥ 2 leukopaenia occurs in 42% of these patients with standard immunosuppression therapy. The gene variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.IMMUNOSUPPRESSION:start with 50% of the standard doseAdjustment of the initial dose should be performed based on toxicity (monitoring of the', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: What is the effect of phenotype of SLCO1B1 Normal Function on fluvastatin dosage?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020SLCO1B1 521TC: fluvastatine4059NO action is required for this gene-drug interaction.The gene variation increases the plasma concentration of fluvastatin, but there is insufficient evidence to prove an effect on efficacy or side effects.Literature:1. Hirvensalo P et al. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther 2019;106:668-80.2. Mori D et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019;34:78-86.3. Xiang Q et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics 2018;28:261-7.4. Meyer zu Schwabedissen HE et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics  9, 1217-27 (2008). (116) Xiang, Q. et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics  28, 261-7 (2018). (117) Deng, J.W. et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics  18, 424-33 (2008). (118) Xiang, Q. et al. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. Asian J Pharm Sci  15, 264-72 (2020). (119) Hirvensalo, P. et al. Enantiospecific Pharmacogenomics of Fluvastatin. Clin Pharmacol Ther  106, 668-80 (2019). (120) Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1013Table 2 Dosing recommendations for statins based on SLCO1B1 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nAll statins\nSLCO1B1 increased \nfunctionTypical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nSLCO1B1 normal function Typical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nAtorvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='-Date 14-12-2005CYP2D6 UM: flupentixol1533This is NOT a gene-drug interaction.No studies have been published in which the kinetics and the effects of flupentixol were studied for this phenotype.Literature:-Date 14-12-2005SLCO1B1 521CC: fluvastatine4060NO action is required for this gene-drug interaction.The gene variation increases the plasma concentration of fluvastatin, but there is insufficient evidence to prove an effect on efficacy or side effects.Literature:1. Hirvensalo P et al. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther 2019;106:668-80.2. Mori D et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019;34:78-86.3. Xiang Q et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics 2018;28:261-7.4. Meyer zu Schwabedissen HE et al.', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: My patient has a SLCO1B1 Possible Decreased Function. How does this impact pitavastatin dosage?
retrieved_docs: [Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the effect of a pgx result of SLCO1B1 Indeterminate on lovastatin dosage?
retrieved_docs: [Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has the following phenotypes -SLCO1B1 Poor Function. How does this impact their atorvastatin dosage?
retrieved_docs: [Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1013Table 2 Dosing recommendations for statins based on SLCO1B1 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nAll statins\nSLCO1B1 increased \nfunctionTypical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nSLCO1B1 normal function Typical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nAtorvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: I take pravachol for my cholesterol. My doctor recently ordered a genetic test for me and I just got the results. It looks like I have something called SLCO1B1 increased function. What does this mean for my cholesterol or pravachol?
retrieved_docs: [Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: How does SLCO1B1 increased function affect rosuvastatin dosage?
retrieved_docs: [Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='possible SLCO1B1 decreased \nfunctionPrescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nPrescriber should be aware \nof possible increased risk for \nmyopathy especially for doses >20 \nmg. STRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. Prescriber should \nbe aware of possible increased \nrisk for myopathy especially for \ndoses >20 mg. MODERATEPrescribe ≤10 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >10 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 poor function Prescribe ≤20 mg as a starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are the implications of having SLCO1B1 possible decreased function when taking pravastatin?
retrieved_docs: [Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPravastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pravastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤40\xa0mgPrescribe desired starting dose and adjust doses of \npravastatin based on disease-  specific guidelines. \nPrescriber should be aware of possible increased \nrisk for myopathy with pravastatin especially with \ndoses >40\xa0mg per dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathyTable 2  (Continued)\n (Continued)\nCPIC UPDATE', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: How does CYP2C9 poor metabolizer status affect simvastatin prescription?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='26 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Kirschheiner, et al. (2003) (192) Hirvensalo, et al. (2019) (119) Clinical CYP2C9*2 or *3 allele is associated with greater odds of developing fluvastatin-induced adverse effects (liver and muscle toxicity). Mirosevic, et al. (2013) (186) Moderate Unknown Statins, CYP2C9 genotypes are not significantly associated with muscle tox or lipid response to statins (simvastatin, fluvastatin, rosuvastatin). Zuccaro, et al. (2007) (193) Weak Clinical A case with liver cirrhosis who experienced fluvastatin-induced fatal rhabdomyolysis. This patient had been treated with simvastatin (20 mg/day) for coronary artery disease and was switched to fluvastatin (20 mg/day) 10 days before admission. Baek, et al. (2011) (194) Weak Clinical CYP2C9*3 is not associated with LDL response to rosuvastatin. Bailey, et al. (2010) (148) Moderate  Clinical CYP2C9*3 allele is associated with an increased concentration of pitavastatin. Zhou,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has SLCO1B1 normal function. How does this impact their pitavastatin dosage?
retrieved_docs: [Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the effect of SLCO1B1 poor function on atorvastatin dosage?
retrieved_docs: [Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='leads to reduced simvastatin transport to the liver, which increases the simvastatin plasma concentration and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39%and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option:1. Avoid simvastatin doses', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's pgx results just came back. She is a CYP2C9 poor metabolizer and also appears to have SLCO1B1 decreased function, what should I do about her prescription?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *29/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *29/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *29/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *29/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*39  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *29/*39  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *28/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *24/*29  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*29  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*39  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *29/*35  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: Is a person with CYP2C9 poor metabolizer and to have SLCO1B1 poor function at increased risk of myopathy if they take fluvastain?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are rosuvastatin dosage implications for ABCG2 poor and SLCO1B1 decreased function?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: Apparently I have something called  ABCG2 decreased function and SLCO1B1 poor function and this might affect my rosuvastatin prescription? Can you help me understand this better?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has SLCO1B1 decreased fucntion. I did not test her for ABCG2 or CYP2C9. Do I need to make any changes to her rosuvastatin dose? I currently have her on the standard dose. She has not complained of myopathy.
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: How should I adjust the dosage of rosuvastatin for a patient with ABCG2 decreased function and SLCO1B1 normal function?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1016\nTable 3 Dosing recommendations for rosuvastatin based on ABCG2 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nNormal function Typical myopathy risk and rosuvastatin \nexposurePrescribe desired starting dose and \nadjust doses of rosuvastatin based on \ndisease-  specific and population-  specific \nguidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and \nhepatic function and Asian ancestry \nshould be evaluated prior to initiating \nrosuvastatin\nDecreased \nfunctionIncreased rosuvastatin exposure as \ncompared with normal function; unknown \nrisk for myopathy; increased lipid-  lowering \neffectsPrescribe desired starting dose and \nadjust doses of rosuvastatin based \non disease-  specific guidelines and \npopulation-  specific guidelinesModerate The potential for drug–  drug interactions \nand dose limits based on renal and', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='possible SLCO1B1 decreased \nfunctionPrescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nPrescriber should be aware \nof possible increased risk for \nmyopathy especially for doses >20 \nmg. STRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. Prescriber should \nbe aware of possible increased \nrisk for myopathy especially for \ndoses >20 mg. MODERATEPrescribe ≤10 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >10 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 poor function Prescribe ≤20 mg as a starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='starting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >20 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 normal function Prescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nSTRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. MODERATEPrescribe ≤20 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >20 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 decreased function or \npossible SLCO1B1 decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's genetic test shows both CYP2C9 normal metabolizer and SLCO1B1 possible decreased function. What does this mean for their fluvastatin prescription?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 decreased function. Thise patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What drug should I order for a phenotype of SLCO1B1 Possible Decreased Function and ABCG2 Decreased Function?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*12 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*10 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*29 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*30 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*19 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*12 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*13 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*26 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*23 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What are the guidelines for SLCO1B1 Poor Function and ABCG2 Decreased Function ?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*23 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*12 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has SLCO1B1 Normal Function and ABCG2 Normal Function. What are the drug dosage guidelines?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content="\ufeffPatients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 reference (G)' display ABCG2 Normal Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient's Pgx results indicate SLCO1B1 Increased Function and ABCG2 Normal Function, her SLCO1B1 diplotype is *14/*14. What should I know about appropriate drug dosage?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*14 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*49 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*14 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*12 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*44 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*48 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What is SAMS risk for a patient with SLCO1B1 Increased Function and ABCG2 Poor Function ?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *29/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *19/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *29/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *19/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *29/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *19/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: How should I adjust fluvastation dose for my patient with CYP2C9 poor metabolizer? They were not tested on SLCO1B1.
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 Indeterminate,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Because CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1017Table 4 Dosing recommendations for fluvastatin based on CYP2C9 phenotype in adults\nPhenotype Implication Dosing recommendationsClassification of \nrecommendationsaConsiderations\nCYP2C9 normal metabolizer Normal exposure Prescribe desired starting dose and \nadjust doses of fluvastatin based on \ndisease-  specific guidelinesStrong The potential for drug–  drug \ninteractions and dose limits \nbased on renal and hepatic \nfunction should be evaluated prior \nto initiating a statin\nCYP2C9 intermediate metabolizer AS \nof 1 and 1.5Increased fluvastatin exposure as \ncompared with normal metabolizer, \nwhich may translate to increased \nmyopathy riskPrescribe ≤40\xa0mg per day as a \nstarting dose and adjust doses of \nfluvastatin based on disease-  specific \nguidelines. If dose >40\xa0mg needed \nfor desired efficacy, consider an \nalternative statin or combination \ntherapy (i.e., fluvastatin plus nonstatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: I ordered a pgx test for my patient before prescribing fluvastatin. The SLCO1B1 result was indeterminate and the CYP2C9 gene shows intermediate metabolizer. Can I prescrible recommended dosage or should I adjust dosage based on their pgx result?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 Indeterminate,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Because CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has SLCO1B1 decreased fucntion. I did not test her for ABCG2 or CYP2C9. Do I need to make any changes to her fluvastatin dose? I currently have her on the standard dose. She has not complained of myopathy.
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient is CYP2C9 normal metabolizer and SLCO1B1 poor function. Does this affect her statin dosing?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient is CYP2C9 poor metabolizer and SLCO1B1 poor function. Does this affect her statin dosing?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient takes Lescol and complained of muscle pains. I orderded a pgx test targeting statins. His results show CYP2C9 intermediate metabolizer and SLCO1B1 possible decreased function. What does this mean for his lescol.
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's pgx result shows poor function for both ABCG2 and SLCO1B1. How does this affect her statin dosing?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's pgx result shows ABCG2 poor function and SLCO1B1 normal function. How does this affect her statin dosing?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: Does ABCG2 normal function and SLCO1B1 increased function impact rosuvastatin prescription?
retrieved_docs: [Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are the implications on Crestor dosage for SLCO1B1 increased function and ABCG2 poor function?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has a SLCO1B1 possible decreased function and is currently take Lipitor. What are the risks?
retrieved_docs: [Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the generic name for brand Livalo ?
retrieved_docs: [Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are the risks of pravachol on a *20/*37 diplotype ?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *37/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*39  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *30/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*50  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *35/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*55  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *24/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What are the risks of pravachol on a SLCO1B1 Poor Function phenotype ?
retrieved_docs: [Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*49 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*31 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*9 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What phenotype function causes increased myopathy risk for mevacor?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *31/*35  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*35  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*26  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*35  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *35/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *15/*26  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*30  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *35/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What SLCO1B1 phenotype function causes increased myopathy risk for mevacor?
retrieved_docs: [Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020SLCO1B1 521TC: simvastatine4055When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore) 2015;94:e1268.6. Luzum JA et al. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. J Cardiovasc Pharmacol 2015;66:80-5.7. Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Hopewell JC et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='16 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S1.  EVIDENCE LINKING SLCO1B1 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References Level of Evidence Atorvastatin In vitro SLCO1B1 is the major atorvastatin uptake transporter.  The average contribution to atorvastatin uptake was SLCO1B1 > SLCO1B3 >> OATP2B1 > NTCP. Vildhede, et al. (2014) (83) Weak In vitro  SLCO1B1 rs4149056 (c.521T>C, *5) reduces atorvastatin transport activity by decreasing OATP1B1 function due to sorting errors in transporter localization Kameyama, et al. (2005) (84) Weak Clinical SLCO1B1 rs4149056 (c.521T>C) C allele is associated with an increased risk of atorvastatin-induced myopathy. Puccetti, et al. (2010) (85) Brunham, et al. (2012) (86) Santos, et al. (2012) (87) Hou, et al. (2015) (88) Hubacek, et al. (2015) (89) Mirosevic, et al. (2015) (90) Liu, et al. (2017) (91) Xiang, et al. (2018) (92) Du, et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='test information by providers and is available at http://www.ncbi.nlm.nih.gov/gtr/.   LINKING GENETIC VARIABILITY TO VARIABILITY IN DRUG-RELATED PHENOTYPES  SLCO1B1. Both SLCO1B1 decreased and poor function phenotypes are associated with increased exposure for most statins, with greater effects of poor function phenotypes.  Effects on exposure also vary by statin type (Figure S1). Therefore, the risk of SAMS varies based on statin type and statin dose. For simvastatin, the evidence linking SAMS to SLCO1B1 rs4149056 (c.521T>C) is of high quality, and this association has been reproduced in retrospective studies of randomized trials and clinical practice-based cohorts (Table S1). This variant is present in several SLCO1B1 star alleles including the relatively common SLCO1B1*5 and *15 alleles. Although the association of rs4149056 with myopathy varies by statin, there is evidence supporting the role of SLCO1B1 variants in the systemic clearance of all statins (3) (Table S1).  Pasanen et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='21 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Clinical SLCO1B1*5 (rs4149056) (c.521T>C) is associated with an increased risk of statin-induced myopathy. Voora, et al. (2009) (156) Hubacek, et al. (2015) (89) Khine, et al. (2016) (157) Bakar, et al. (2018) (135) C. Thambiah, et al. (2019) (138) Floyd, et al. (2019) (158) Weak Clinical Presence of the SLCO1B1 rs4149056 (c.521T>C)  C allele is associated with increased risk of composite adverse events when treated with statins (atorvastatin, pravastatin or simvastatin) in patients with hypercholesterolemia. Voora, et al. (2009) (156) Carr, et al. (2013) (159) Moderate Clinical  SLCO1B1 rs4149056 (c.521T>C) C allele is associated with an increased LDL-C levels in statin-treated patients. Li, et al. (2015) (151) Moderate Clinical SLCO1B1 rs2306283 (c.388A>G) is not associated with an increased LDL-C levels in statin-treated patients. Li, et al. (2015) (151) Moderate Clinical Genetically guided statin therapy', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 37  (94) Ramakumari, N., Indumathi, B., Katkam, S.K. & Kutala, V.K. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J  70 Suppl 3, S120-S5 (2018). (95) Mori, D. et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet  34, 78-86 (2019). (96) Linskey, D.W. et al. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics  30, 208-11 (2020). (97) Turner, R.M. et al. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clin Pharmacol Ther  108, 287-97 (2020). (98) Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M. & Mushiroda, T. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 38  (111) Prado, Y., Saavedra, N., Zambrano, T., Lagos, J., Rosales, A. & Salazar, L.A. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci  16, 20609-19 (2015). (112) Mladenovska, K. et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie  72, 288-95 (2017). (113) de Keyser, C.E. et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics  24, 43-51 (2014). (114) Kadam, P., Ashavaid, T.F., Ponde, C.K. & Rajani, R.M. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther  41, 329-33 (2016). (115) Couvert, P. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='*1a. Iwai, et al. (2004) (131) Kameyama, et al. (2005) (84)  Ho, et al. (2006) (132)  Moderate Clinical SLCO1B1 rs4149056 (c.521T>C) C allele is associated with an increased risk of simvastatin-induced myopathy. Link, et al. (2008) (133) Brunham, et al. (2012) (86) Hubacek, et al. (2015) (89) Liu, et al. (2017) (91) Shek, et al. (2017) (134) Bakar, et al. (2018) (135) Flores-Unzueta, et al. (2018) (136) Xiang, et al. (2018) (92) Carr, et al. (2019) (137) C. Thambiah, et al. (2019) (138)  High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has SLCO1B1 increased function. Does this cause increased myopathy risk for mevacor?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore) 2015;94:e1268.6. Luzum JA et al. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. J Cardiovasc Pharmacol 2015;66:80-5.7. Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Hopewell JC et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the brand name for rosuvastatin?
retrieved_docs: [Document(page_content='31 Figure 3. Major CV Events by Treatment Group in JUPITER  \n \nAt one year, rosuvastatin increased HDL -C and reduced LDL -C, hsCRP, total cholesterol and \nserum triglyceride levels (p  <0.001 for all versus placebo).  \n16 HOW SUPPLIED/STORAGE AND HANDLING \nCRESTOR® (rosuvastatin calcium) Tablets are supplied as:  \n• NDC 0310-0755-90: 5 mg. Yellow, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “5” on one side; bottle of 90 tablets  \n• NDC 0310-0751-90: 10 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “10” on one side; bottle of 90 tablets  \n• NDC 0310-0751-39: 10 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “10” on one side; unit dose packages of 100 \n• NDC 0310-0752-90: 20 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “20” on one side; bottles of 90 \n• NDC 0310-0752-39: 20 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “20”on one side; unit dose packages of 100', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='33  \nPATIENT INFORMATION  \nCRESTOR®(Kres-tor) \nrosuvastatin calcium  \nTablets  \nRead this Patient Information carefully before you start taking CRESTOR and each \ntime you get a refill. If you have any questions about CRESTOR, ask your doctor. \nOnly your doctor can determine if CRESTOR is right for you.  \nWhat is CRESTOR?  \nCRESTOR is a prescription medicine that contains a cholesterol -lowering medicine \ncalled rosuvastatin calcium . Most of the cholesterol in your blood is made in the liver. \nCRESTOR works by reducing cholesterol in two ways: CRESTOR blocks an  enzyme in \nthe liver causing the liver to make less cholesterol, and CRESTOR increases the \nuptake and breakdown by the liver of cholesterol already in the blood.  \n \n• CRESTOR is used along with diet to:  \no lower the level of your “bad” cholesterol (LDL)  \no increase the level of your “good” cholesterol (HDL)  \no lower the level of fat in your blood (triglycerides)', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='In a double -blind, randomized, mult icenter, placebo -controlled, 12-week study, 176 (97 male and \n79 female) children and adolescents with heterozygous familial hypercholesterolemia were \nrandomized to rosuvastatin 5, 10 or 20 mg or placebo daily. Patients ranged in age from 10 to \n17 years (median age of 14 years) with approximate ly 30% of the patients 10 to 13 years and \napproximately 17%, 18%, 40%, and 25% at Tanner stages II, III, IV, and V, respectively. Females were at leas t 1 year postmenarche. Mean LDL -C at baseline was 233  mg/d L (range of \n129 to 399). The 12-week double -blind phase was followed by a 40 week open label dose -\ntitration phase, where all patients (n=173) received 5 mg, 10 mg or 20 mg rosuvastatin daily.  \nRosuvastatin significantly reduced LDL -C (primary end point), total cholesterol and ApoB levels \nat each dose compared to placebo.  Results are shown in Table  12 below.', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='calcium salt with the following structural formula:  \n \nThe empirical formula for rosuvastatin calcium is (C 22H27FN 3O6S)2Ca an d the molecular weight \nis 1001.14. Rosuvastatin calcium is a white amorphous powder that is sparingly soluble in water \nand methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water ) of  0.13 at pH of  7.0.  \nCRESTOR Tablets for oral administration contain 5, 10, 20, or 40 mg of rosuvastatin and the \nfollowing inactive ingredients: Each tablet contains: microcrystalline cellulose NF, lactose monohydrate NF, tribasic calcium phosphate NF , crospovidone NF, magnesium stearate NF, \nhypromellose NF, triacetin NF, titanium dioxide USP, yellow ferric oxide, and red ferric oxide \nNF. \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='taking rosuvastatin (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly \nincreased by 0.1% in rosuvastatin-treated patients compared to placebo -treated patients. The \nnumber o f patients with a HbA1c  >6.5% at the end of the trial was significantly higher in \nrosuvastatin-treated versus placebo -treated patients [see Warnings and Precautions (5.5)\n and \nClinical Studies (14. 9)].  \nAdverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in \nTable  3. \nTable  3. Adverse Reactions1 Reported in ≥2% of Patients Treated with \nCRESTOR and >  Placebo in the JUPITER Trial (% of Patients)  \nAdverse Reactions  CRESTOR 20  mg \nN=8901  Placebo  \nN=8901  \nMyalgia  7.6 6.6 \nArthralgia  3.8 3.2 \nConstipation  3.3 3.0 \nDiabetes mellitus  2.8 2.3 \nNausea  2.4 2.3 \n1 Treatment -emergent adverse reactions by MedDRA preferred term.  \nPediatric Patients with Heterozygous Familial Hype rchole sterol emia', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='16 patients [see Contraindications (4) , Warning and Precautions (5.2)  and Clinical Pharmacology \n(12.3) ]. \n8.8 Asian Patients \nPharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure \nto rosuvastatin in Asian subjects when compared with Caucasian controls. CRESTOR dosage \nshould be adjusted in Asian patients [ see Dosage and Administration (2.3 ) and Clinical \nPharmacology (12.3) ]. \n10 OVERDOSAGE  \nThere is no specific treatment in the event of overdose. In the event of overdose, the patient \nshould be treated symptomatically and supportive  measures instituted as required. Hemodialysis \ndoes not significantly enhance clearance of rosuvastatin.  \n11 DESCRIPTION \nCRESTOR (rosuvastatin calcium) is a synthetic lipid-lowering agent for oral administration.  \nThe chemical name for rosuvastatin calcium is bis[(E) -7-[4-(4-fluorophenyl) -6-isopropyl -2-\n[methyl(methylsulfonyl)amino] pyrimidin-5 -yl](3R,5S) -3,5-dihydroxyhept -6-enoic acid]', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='18 Metabolism  \nRosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is \nrecovered as metabolite. The major metabolite is N -desmethyl rosuvastatin, which is formed \nprincipally by cytochrome P450 \\ 2C9, and in vitro  studies have demonstrated that N -desmethyl \nrosuvastatin has approximately one -sixth to one -half the HMG -CoA reductase inhibitory activity \nof the parent compound. Overall, greater than 90% of active plasma HMG -CoA reductase \ninhibitory activity is accounted for by the parent compound.  \nExcretion  \nFollowing oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%).  After an intravenous dose, approximately 28% of total body clearance was via the renal \nroute, and 72% by the hepatic route.  \nSpecific Populations  \nRacial or Ethnic Groups', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='The primary end point was a composite end point consisting of the time -to-first occurrence of \nany of the following major CV events: CV death, nonfatal myocardial infarction, nonfatal stroke, \nhospitalization for unstable angina or an arterial revascularization procedure.  \nRosuvastatin significantly reduced the risk of major CV events (252 events in the placebo group vs. 142 events in the rosuvastatin group) with a statistically significant (p<  0.001) relative risk \nreduction of 44% and absolute risk reduction of 1.2% (see Figure 2). The risk reduction for the \nprimary end point was consistent across the following predefine d subgroups: age, sex, race, \nsmoking status, family history of premature CHD, body mass index, LDL -C, HDL -C, and \nhsCRP levels.  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circ Genom Precis Med  11, e002228 (2018). (162) Shek, A.B. et al. Personalized rosuvastatin therapy in problem patients with partial statin intolerance. Arch Med Sci Atheroscler Dis  3, e83-e9 (2018). (163) Keskitalo, J.E., Pasanen, M.K., Neuvonen, P.J. & Niemi, M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics  10, 1617-24 (2009). (164) Kitamura, S., Maeda, K., Wang, Y. & Sugiyama, Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos  36, 2014-23 (2008). (165) Huang, L., Wang, Y. & Grimm, S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos  34, 738-42 (2006).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='1 HIGHLIGHTS OF PRESCRIBING INFORMATION  \nThese highlights do not include all the information needed to use \nCRESTOR safely and effectively. See full prescribing information for \nCRESTOR.  \n CRESTOR (rosuvastatin calcium) tabl ets \nInitial U.S. Approval: 2003 \n \n------------------------ INDICATIONS AND USAGE ---------------------------- \nCRESTOR is an HMG Co -A reductase inhibitor indicated f or:  \n• adult patients with primary hyperlipidemia and mixed dyslipidemia as an \nadjunct to diet to reduce elevated total -C, LDL -C, ApoB , nonHDL -C, and  \nT G levels and to increase HDL -C (1.1)  \n• pediatric patients 8 to 17 years of  age with heterozygous f amilial \nhypercholesterolemia (HeFH) to reduce elevated total -C, LDL -C and \nApoB af ter f ailing an adequate trial of  diet therapy (1.2)   \n• pediatric patients 7  to 17 years of  age with homozygous f amilial \nhypercholesterolemia (HoFH) to reduce LDL -C, total-C, nonHDL -C and', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the brand name for fluvastatin?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 decreased function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 decreased function. Thise patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 possible decreased function. Thise patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 possible decreased function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the brand name for simvastatin?
retrieved_docs: [Document(page_content='response to simvastatin. Arterioscler Thromb Vasc Biol  30, 1485-92 (2010).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='J Heart Lung Transplant  14, 613-22 (1995). (43) Vanhaecke, J., Van Cleemput, J., Van Lierde, J., Daenen, W. & De Geest, H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation  58, 42-5 (1994). (44) Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther  78, 330-41 (2005). (45) Feng, Q., Wilke, R.A. & Baye, T.M. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics  13, 579-94 (2012). (46) Brunham, L.R. et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J,  (2011). (47) Giorgi, M.A., Caroli, C., Arazi, H.C. & Di Girolamo, G. Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opin Pharmacother  12, 1499-509 (2011). (48) He, Y.J. et al. Rifampicin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='another drug during simvastatin and atorvastatin therapy. Becker, et al. (2010) (218) Weak Clinical  CYP3A4*22 is associated with lower statin dose (atorvastatin, simvastatin, or lovastatin). Wang, et al. (2011) (219) Weak Clinical  CYP3A5*3 is associated with cholesterol response to simvastatin. Kivisto, et al. (2004) (220) Fiegenbaum, et al. (2005) (221) Hu, et al. (2013) (222) Kolovou, et al. (2014) (223) Kitzmiller, et al. (2017) (152) Weak', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CRESTOR 20  mg 17 -40 -55 -51 -46 -23 8 \nCRESTOR 40  mg 18 -46 -63 -60 -54 -28 10 \n \nActive -Controlled Study:  CRESTOR was compared with the HMG -CoA reductase inhibitors \natorvastatin, simvastatin, and pravastat in in a multicenter, open-la bel, dose -ranging study of \n2240 patients with hyperlipidemia or mixed dyslipidemia. After randomizati on, patients were \ntreated for 6  weeks with a single daily dose of either CRESTOR, atorvastatin, simvastatin, or \npravastatin (Fi gure 1 and Table  7). \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 35  (57) Hamelin, B.A. & Turgeon, J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci  19, 26-37 (1998). (58) Rehman, M.A. et al. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine. Transplantation  60, 397-9 (1995). (59) Arnadottir, M., Eriksson, L.O., Germershausen, J.I. & Thysell, H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron  68, 57-62 (1994). (60) Arnadottir, M., Eriksson, L.O., Thysell, H. & Karkas, J.D. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron  65, 410-3 (1993). (61) Ide,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 34  (39) Stein, C.M., Sadeque, A.J., Murray, J.J., Wandel, C., Kim, R.B. & Wood, A.J. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clinical pharmacology and therapeutics  69, 317-23 (2001). (40) Capone, D., Stanziale, P., Gentile, A., Imperatore, P., Pellegrino, T. & Basile, V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol  19, 411-5 (1999). (41) Lepre, F., Rigby, R., Hawley, C., Saltissi, D., Brown, A. & Walsh, Z. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clin Transplant  13, 520-5 (1999). (42) Pflugfelder, P.W., Huff, M., Oskalns, R., Rudas, L. & Kostuk, W.J. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant  14, 613-22 (1995). (43)', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='frequency, allele functionality, diplotype to phenotype tables have all been updated and reformatted and are now available at https://cpicpgx.org/guidelines/cpic-guideline-for-statins/   LITERATURE REVIEW We searched the PubMed database (1966 to July 2021) using the following keyword strategies: SLCO1B1: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (SLCO1B1 OR OATP1B1) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response OR reaction) NOT ("review"[Publication Type]) AND English[lang] AND ("2014/01/01"[PDAT] : "2021/07/20"[PDAT]) ABCG2: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (ABCG2 OR BCRP) AND (myopathy', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and atorvastatin therapy. Pharmacoepidemiol Drug Saf  19, 75-81 (2010).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: What is the generic name for Zocor?
retrieved_docs: [Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='the tablet.  \n40 mg: Pink, oval, biconvex, coated tablets. Debossed “CRESTOR” on one side and “40” on the \nother side of the tablet.  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the generic name for Crestor?
retrieved_docs: [Document(page_content='the tablet.  \n40 mg: Pink, oval, biconvex, coated tablets. Debossed “CRESTOR” on one side and “40” on the \nother side of the tablet.  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='33  \nPATIENT INFORMATION  \nCRESTOR®(Kres-tor) \nrosuvastatin calcium  \nTablets  \nRead this Patient Information carefully before you start taking CRESTOR and each \ntime you get a refill. If you have any questions about CRESTOR, ask your doctor. \nOnly your doctor can determine if CRESTOR is right for you.  \nWhat is CRESTOR?  \nCRESTOR is a prescription medicine that contains a cholesterol -lowering medicine \ncalled rosuvastatin calcium . Most of the cholesterol in your blood is made in the liver. \nCRESTOR works by reducing cholesterol in two ways: CRESTOR blocks an  enzyme in \nthe liver causing the liver to make less cholesterol, and CRESTOR increases the \nuptake and breakdown by the liver of cholesterol already in the blood.  \n \n• CRESTOR is used along with diet to:  \no lower the level of your “bad” cholesterol (LDL)  \no increase the level of your “good” cholesterol (HDL)  \no lower the level of fat in your blood (triglycerides)', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='CRESTOR 20  mg 17 -40 -55 -51 -46 -23 8 \nCRESTOR 40  mg 18 -46 -63 -60 -54 -28 10 \n \nActive -Controlled Study:  CRESTOR was compared with the HMG -CoA reductase inhibitors \natorvastatin, simvastatin, and pravastat in in a multicenter, open-la bel, dose -ranging study of \n2240 patients with hyperlipidemia or mixed dyslipidemia. After randomizati on, patients were \ntreated for 6  weeks with a single daily dose of either CRESTOR, atorvastatin, simvastatin, or \npravastatin (Fi gure 1 and Table  7). \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='36 hypromellose NF, triacetin NF, titanium dioxide USP, yellow ferric oxide, and red \nferric oxide NF.   \nGeneral Information about the safe and effective use of CRESTOR  \nMedicines are sometimes prescribed for purposes other than those listed in a Patient \nInformat io n leaflet. Do not use CRESTOR for a condition for which it was not \nprescribed. Do not give CRESTOR to other people, even if they have the same medical condition you have. It may harm them.  \n \nYou can ask your pharmacist or doctor for information about CREST OR that is written \nfor health professionals.   \nCRESTOR is a trademark of the AstraZeneca group of companies.  \n© AstraZeneca 2018 \nLicensed from SHIONOGI & CO., LTD., Osaka, Japan  \nDistributed by:  \nAstraZeneca Pharmaceuticals LP  \nWilmington, DE 19850  \nFor mor e information, go to the CRESTOR website at www.crestor.com or call 1 -800-CRESTOR  \nThis Patient Information has been approved by the U.S. Food and D rug Administration               Revised 9/2018', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='1 HIGHLIGHTS OF PRESCRIBING INFORMATION  \nThese highlights do not include all the information needed to use \nCRESTOR safely and effectively. See full prescribing information for \nCRESTOR.  \n CRESTOR (rosuvastatin calcium) tabl ets \nInitial U.S. Approval: 2003 \n \n------------------------ INDICATIONS AND USAGE ---------------------------- \nCRESTOR is an HMG Co -A reductase inhibitor indicated f or:  \n• adult patients with primary hyperlipidemia and mixed dyslipidemia as an \nadjunct to diet to reduce elevated total -C, LDL -C, ApoB , nonHDL -C, and  \nT G levels and to increase HDL -C (1.1)  \n• pediatric patients 8 to 17 years of  age with heterozygous f amilial \nhypercholesterolemia (HeFH) to reduce elevated total -C, LDL -C and \nApoB af ter f ailing an adequate trial of  diet therapy (1.2)   \n• pediatric patients 7  to 17 years of  age with homozygous f amilial \nhypercholesterolemia (HoFH) to reduce LDL -C, total-C, nonHDL -C and', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='16 patients [see Contraindications (4) , Warning and Precautions (5.2)  and Clinical Pharmacology \n(12.3) ]. \n8.8 Asian Patients \nPharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure \nto rosuvastatin in Asian subjects when compared with Caucasian controls. CRESTOR dosage \nshould be adjusted in Asian patients [ see Dosage and Administration (2.3 ) and Clinical \nPharmacology (12.3) ]. \n10 OVERDOSAGE  \nThere is no specific treatment in the event of overdose. In the event of overdose, the patient \nshould be treated symptomatically and supportive  measures instituted as required. Hemodialysis \ndoes not significantly enhance clearance of rosuvastatin.  \n11 DESCRIPTION \nCRESTOR (rosuvastatin calcium) is a synthetic lipid-lowering agent for oral administration.  \nThe chemical name for rosuvastatin calcium is bis[(E) -7-[4-(4-fluorophenyl) -6-isopropyl -2-\n[methyl(methylsulfonyl)amino] pyrimidin-5 -yl](3R,5S) -3,5-dihydroxyhept -6-enoic acid]', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='20 mg or placebo in random order , followed by a 12-week open-label  phase during which all \npatients received  CRESTOR 20  mg. Patients ranged in age from 7 to 15 years of age (median 11 \nyears), 50% were male, 71% were Caucasian, 21% were Asian, 7% were Black, and no patients \nwere of Hispanic ethnicity. Fifty percent were on apheresis therapy and 57% were taking \nezetimibe. Patients who entered the study on apheresis therapy or ezetimibe continued the \ntreatment throughout the entire study.  Mean LDL -C at baseline was 416  mg/dL (range 152 to \n716 mg/dL). A total of 13 patients completed both treatment periods of the randomized cross -\nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='adult patients with homozygous familial hypercholesterolemia.  \n1.6 Slowing of the Progression of Atherosclerosis \nCRESTOR is indicated as adjunctive therapy to diet to slow the progression of atheroscler osis in \nadult patients as part of a treatment strategy to lower Total -C and LDL -C to target levels.  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='31 Figure 3. Major CV Events by Treatment Group in JUPITER  \n \nAt one year, rosuvastatin increased HDL -C and reduced LDL -C, hsCRP, total cholesterol and \nserum triglyceride levels (p  <0.001 for all versus placebo).  \n16 HOW SUPPLIED/STORAGE AND HANDLING \nCRESTOR® (rosuvastatin calcium) Tablets are supplied as:  \n• NDC 0310-0755-90: 5 mg. Yellow, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “5” on one side; bottle of 90 tablets  \n• NDC 0310-0751-90: 10 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “10” on one side; bottle of 90 tablets  \n• NDC 0310-0751-39: 10 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “10” on one side; unit dose packages of 100 \n• NDC 0310-0752-90: 20 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “20” on one side; bottles of 90 \n• NDC 0310-0752-39: 20 mg. Pink, round, biconvex, coated tablets. Debossed \n“CRESTOR” and “20”on one side; unit dose packages of 100', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='17 12 CLINICAL PHARMACOLOGY  \n12.1 Mechanism of Action  \nCRESTOR is a selective and competitive inhibitor of HMG -CoA reduc tase, the rate-limiting \nenzyme that converts 3-hydroxy-3 -methylglutaryl coenzyme A to mevalonate, a precursor of \ncholesterol. In vivo  studies in animals, and in vitro  studies in cultured animal and human cells \nhave shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the \ntarget o rgan for cholesterol lowering. In in vivo  and in vitro  studies, rosuvastatin produces its \nlipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on \nthe cell -surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic \nsynthesis of VLDL, which reduces the total number of VLDL and LDL particles.  \n12.2 Pharmacodynamics \nCRESTOR dose dependently r educes elevated LDL -cholesterol  and reduces  total cholesterol and', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='• NDC 0310-0754-30: 40 mg. Pink, oval, biconvex, coated tablets . Debossed “CRESTOR” \non one side and “40” on the other side; bottles of 30 \nStorage  \nStore at controlled room temperature, 20-25ºC (68-77ºF) [see USP Controlled Room \nTemperature].  Protect from moisture.  \n17 PATIENT COUNSELING INFORMATION \nAdvise the patient t o read the FDA -approved patient labeling (Patient Information).  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='o slow the buildup of fatty deposits (plaque) in the walls of blood vessels  \n• CRESTOR is used to treat:  \no adults  who cannot control their cholesterol levels by diet a nd exercise alone  \no children 8 to 17 years of age with heterozygous familial hypercholesterolemia (an \ninherited condition that causes high levels of LDL)  \no children 7 to 17 years of age with homozygous familial hypercholesterolemia (an \ninherited condition tha t causes high levels of LDL) . \n \nCRESTOR is not approved for use in children with heterozygous familial \nhypercholesterolemia younger than 8 years of age  or for use in children with \nhomozygous familial hypercholesterolemia younger than 7 years of age . \n \nCRESTO R is used to reduce the risk of heart attacks and strokes in men 50 years of \nage and older and women 60 years of age and older who do not have known heart \ndisease but do have certain additional risk factors.', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='CRESTOR. ( 5.1, 7.5, 7.6) \n----------------------- USE IN SPECIFIC POP ULATIONS ------------------- -- \n• Females of reproductive potential:  Advise f emales of  reproductive \npotential to use ef f ective contraception during treatment with CRESTOR \n(8.3)  \n• Severe renal impairment (not on hemodialysis):   Starting dose is 5 mg,  \nnot to exceed 10 mg. ( 2.5, 5.1, 8.6) \n• Asian population: Consider 5 mg starting dose. ( 2.3, 8.8) \n See 17 for PATIENT COUNSELING INFORMATION and FDA-\napproved patient labeling . \nRevised: 9/2018\nFULL PRESCRIBING INFORMATION: CONTENTS\n*\n \n1 INDICATIONS AND USAG E \n1.1 Hyperlipidemia and Mixed Dyslipidemia  \n1.2 Pediatric Patients with Familial Hypercholesterolemia  \n1.3 Hypertriglyceridemia  \n1.4 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)  \n1.5 Adult Patients with Homozygous Familial Hypercholesterolemia  \n1.6 Slowing of  the Progression of  Atherosclerosis  \n1.7 Primary Prevention of  Cardiovascular Disease  \n1.8 Limitations of  Use', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='4 1.7 Primary Prevention of Cardiovascular Disease \nIn individuals without clinically evident coronary heart disease but with an increased risk of \ncardiovascul ar disease based on age ≥50 years old in men and ≥60 years old in wom en, \nhsCRP  ≥2 mg/L, and the presence of at least one additional cardiovascular disease risk factor \nsuch as hypertension, low HDL -C, smoking, or a family history of premature coronary heart  \ndisease, CRESTOR is indicated to:  \n• reduce the risk of stroke  \n• reduce the risk of myocardial infarction \n• reduce the risk of arterial revascularization procedures  \n1.8 Limitations of Use \nCRESTOR has not been studied in Fredrickson Type  I and V dyslipidemias.  \n \n2 DOSAGE AND ADMINISTRATION \n2.1 General Dosing Information  \nThe dose r ange for CRESTOR in adults is 5 to 40 mg orally once daily. The usual starting dose \nis 10 to 20 mg once daily.  The usual starting dose in adult patients with homozygous familial \nhyperchole sterolemia is 20  mg once daily.', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='3 FULL PRESCRIBING INFORMATION \n1 INDICATIONS AND USAGE  \n1.1 Hyperlipidemia and Mixed Dyslipidemia \nCRESTOR is indicated as adjunctive therapy t o diet to reduce elevated Total -C, LDL -C, ApoB, \nnonHDL -C, and triglycerides and to increase HDL -C in adult patients with primary \nhyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet \nrestricted in saturated fat and cholesterol when response to diet and nonpharma cological \ninterventions alone has been inadequate.  \n1.2 Pediatric Patients with Familial Hypercholesterolemia  \nCRESTOR is indicated as an adjunct to diet to:  \n• reduce Total -C, LDL -C and ApoB levels in children and adolescent s 8 to17 years of age \nwith heteroz ygous familial hypercholesterolemia if after an adequate trial of diet therapy \nthe follow ing findings are present: LDL -C >190 mg/dL , or >160 mg/dL along with a', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='The safety and effectiveness of CRESTOR in children and adolescents 10 to 17 years of age with \nheterozygous fami lial hypercholesterolemia were evaluated in a controlled clinical trial of \n12 weeks duration followed by 40 weeks of open-label exposure. Patients treated with 5  mg, \n10 mg, and 20 mg daily CRESTOR had an adverse experience profile generally similar to that  of \npatients treated with placebo. There was no detectable effect of CRESTOR on growth, weight, \nBMI (body mass index), or sexual maturation [see Clinical Studies (14. 7)] in children and \nadolescents  (10 to 17 years of age).  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='• gemfibrozil (a fibric acid medicine for lowering cholesterol)  \n• anti-viral medicines including HIV or hepatitis  C protease inhibitors (such as \nlopinavir, rito navir, fosamprenavir, tipranavir, atazanavir, or simeprevir)  \n• certain anti -fungal medicines (such as itraconazole, ketoconazole and \nfluconazole)  \n• coumarin anticoagulants (medicines that prevent blood clots, such as \nwarfarin)  \n• niacin or nicotinic acid  \n• fibric a cid derivatives (such as fenofibrate)  \n• colchicine (a medicine used to treat gout)  \nAsk your doctor or pharmacist for a list of these medicines if you are not sure.  \nKnow all of the medicines you take. Keep a list of them to show your doctor and \npharmacist whe n you get new medicine.  \nHow should I take CRESTOR?  \n• Take CRESTOR exactly as your doctor tells you to take it.  \n• Take CRESTOR, by mouth, 1 time each day. Swallow the tablet whole.  \n• CRESTOR can be taken at any time of day, with or without food.', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='(12.3) ]. \nPatients taking atazanavir and ritonavir, lopinavir and ritonavir , or simeprevir  \nInitiate CRESTOR therapy with 5  mg once daily. The dose of CRESTOR should not exceed \n10 mg once daily [see Warnings and Precautions (5.1) , Drug Interactions (7.3)  and Clinical \nPharmacology (12.3) ]. \n2.5 Dosing in Patients with Severe Renal Impairment \nFor patients with seve re renal impairment (CL cr <30 mL/min/1.73 m2) not on hemodialysis, \ndosing of CRESTOR should be started at 5 mg once daily and not exceed 10 mg once daily [see \nUse in Specific Populations (8.6)  and Clinical Pharmacology (12.3) ]. \n \n3 DOSAGE FORMS AND STRENGTHS \n5 mg: Yellow, round, biconvex, coated tablets. Debossed “CRESTOR” and “5” on one side of \nthe tablet.  \n10 mg: Pink, round, biconvex, coated tablets. Debossed “CRESTOR” and “10” on one side of \nthe tablet.  \n20 mg: Pink, round, biconvex, coated tablets. Debossed “CRESTOR” and “20” on one side of \nthe tablet.', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='pravastatin 20 mg and 40 mg; simvastatin 20 mg, 40 mg, and 80 mg. (p< 0.002)  \n4 CRESTOR 40  mg reduced LDL -C significantly more than atorvastatin 40 mg; pravastatin 40 mg; \nsimvastatin 40 mg, and 80 mg. (p< 0.002)  \n14.2 Heterozygous Familial Hypercholesterolemia  \nActive -Controlled Study : In a study of patients with heterozygous FH (baseline mean LDL of \n291), patients were randomized to CRESTOR 20 mg or atorvastatin 20 mg. The dose was \nincreased by 6-week intervals. Significant LDL -C reductions from baseline were seen at each \ndose in both treatment groups (Table  8). \nTable  8. Mean LDL -C Per centage Change f r om Baseline  \n  CRESTOR (n=435)  \nLS Me an1 (95% CI)  Atorvastatin (n=187)  \n LS Me an1 (95% CI)  \nWeek 6  20 mg -47% ( -49%, -46%)  -38% ( -40%, -36%)  \nWeek 12  40 mg -55% ( -57%, -54%)  -47% ( -49%, -45%)  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='In a 12-week controlled study in boys and postmenarche al girls  10 to 17 years of age with \nheterozygous familial hypercholesterolemia  with CRESTOR 5  to 20 mg daily [see Use in \nSpecific Populations (8.4)  and Clinical Studies (14.7) ], elevations in serum creatine \nphosphokinase (CK)  >10 x ULN were observed more frequently in rosuvastatin compared with \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'})]

question: What is the generic name for Lescol?
retrieved_docs: [Document(page_content='lovastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='the tablet.  \n40 mg: Pink, oval, biconvex, coated tablets. Debossed “CRESTOR” on one side and “40” on the \nother side of the tablet.  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the generic name for Lipitor?
retrieved_docs: [Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='5 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang]  CYP2C9: (fluvastatin) AND (CYP2C9) HMGCR: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (HMGCR) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR reaction OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response) NOT ("review"[Publication Type]) AND English[lang] CYP3A4/5: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (CYP3A4 OR', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='frequency, allele functionality, diplotype to phenotype tables have all been updated and reformatted and are now available at https://cpicpgx.org/guidelines/cpic-guideline-for-statins/   LITERATURE REVIEW We searched the PubMed database (1966 to July 2021) using the following keyword strategies: SLCO1B1: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (SLCO1B1 OR OATP1B1) AND (myopathy OR myalgia OR discontinuation OR tolerance OR pharmacokinetic OR efficacy OR LDL lowering OR Rhabdomyolysis OR Myositis OR “Statin associated muscle symptoms” OR withdrawal OR intolerance OR hepatocyte uptake OR response OR reaction) NOT ("review"[Publication Type]) AND English[lang] AND ("2014/01/01"[PDAT] : "2021/07/20"[PDAT]) ABCG2: (simvastatin OR rosuvastatin OR pravastatin OR pitavastatin OR atorvastatin OR fluvastatin OR lovastatin OR Caduet OR Vytorin) AND (ABCG2 OR BCRP) AND (myopathy', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Page 12 of 28Accepted Manuscript\n12 \n Pharmacogenetics of statins  \n \nStatins inhibit 3 -hydroxyl -3-methylglutaryl coenzyme A reductase (HMB -CoA reductase). This \nenzyme catalyzes the transformation of HMG -CoA into mevalonate, an early and limiting step of \ncholesterol synthesis. The statin family constitutes the main cholesterol -lowering  option in the  \ntherapeutic armamentarium. The family currently includes the following compounds, listed by order \nof marketing approval: lovastatin (1987), simvastatin, pravastatin, fluvastatin, atorvastatin and \nrosuvastatin (2003). These drugs are mainly cleared by hepato biliary excretion after capture by the \nsolute carrier organic anion transporter family member 1B1 (SLCO1B1), also called organic anion \ntransporting polypeptide family member 1B1 (OATP1B1), expressed on the hepatocyte membrane. \nAdverse effects observed in c ertain patients taking statins include muscle toxicity that varies from', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the generic name for the brand Altoprev?
retrieved_docs: [Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='the tablet.  \n40 mg: Pink, oval, biconvex, coated tablets. Debossed “CRESTOR” on one side and “40” on the \nother side of the tablet.  \nReference ID: 4347984', metadata={'link': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021366s038lbl.pdf', 'source': 'FDA guidelines for CRESTOR (rosuvastatin calcium) tablets, Reference ID: 4347984'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are the implications of taking Mevacor with a SLCO1B1 decreased function phenotype?
retrieved_docs: [Document(page_content='de novo variants are often not tested for within currently available genotyping tests, if discovered, it may be unclear how to act upon such results. Yet, rare exonic variants in SLCO1B1 have been shown to have clinical impact (e.g., methotrexate clearance) (66). Therefore, altered drug kinetics and increased risk for severe drug toxicity may still occur in the absence of a c.521 C allele, and a c.521TT genotype at rs4149056 does not necessarily imply the absence of other potentially function-altering variant(s) in SLCO1B1. Allele and variant function are available on PharmVar.org as well as CPIC’s SLCO1B1Allele Functionality Table (67, 68).  RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN EHR WITH CDS  Clinical decision support (CDS) tools integrated within electronic health records (EHRs) can help guide clinical pharmacogenetics at the point of care (69-73).  See https://cpicpgx.org/guidelines/cpic-guideline-for-statins/ for resources to support the adoption of CPIC guidelines', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*34 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*32 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*10 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*30 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*33 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient is on Zocor. Are there any genetic considerations I should be aware of?
retrieved_docs: [Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='gemfibrozil increases systemic exposure to active simvastatin acid (36) placing patients at increased risk for developing myopathy. Because of interactions such as these, all the statin package labels recommend reducing the dose of statins in patients using concomitant medications known to alter its pharmacokinetics.   The Role of Ancestry.  There is some evidence that Asian Americans are one of three important groups with an elevated risk/benefit ratio for use of some statins compared to other ancestry groups; the other important groups were patients on cyclosporine (CSA)/immune suppression and patients with severe kidney failure) (37-43).Geographic differences in allele frequency for SLCO1B1 rs4149056 (c.521T>C) do not appear to contribute to this sensitivity in Asians (44). For rosuvastatin, this difference appears to be at least partly attributable to variability in efflux transporters such as ABCG2, as well as gene-gene and gene-environment interactions not yet defined (45).  For', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='10 Other Considerations .................................................................................................................... 10 Drug-drug interactions .............................................................................................................. 10 The Role of Ancestry. ............................................................................................................... 11 Other Limitations. ..................................................................................................................... 11 Resources to Incorporate Pharmacogenetics into an EHR with CDS ........................................... 12 Figure S1. Pharmacokinetic impact of rs4149056 genotype for several statins. .......................... 14 Table S1.  Evidence linking SLCO1B1 genotype with Statin phenotype .................................... 16 Table S2.  Evidence linking ABCG2 genotype with Statin phenotype ........................................ 22 Table', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.20. Pasanen MK et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33.21. Hermann M et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006;79:532-9.22. Thompson JF et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020NUDT15 IM: azathioprine/mercaptopurine7035Grade ≥ 2 leukopaenia occurs in 42% of these patients with standard immunosuppression therapy. The gene variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.IMMUNOSUPPRESSION:start with 50% of the standard doseAdjustment of the initial dose should be performed based on toxicity (monitoring of the', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='continuation, thus leading to higher cholesterol levels and a higher \nrisk for cardiovascular disease if statins are not reinitiated.29,30\nLinking genetic variability to variability in drug-  related \nphenotypes\nWe applied a systematic approach to reviewing the evidence un -\nderlying the clinical validity of genetic associations with statin- \nrelated phenotypes including statin pharmacokinetics ( in vivo  \nand in vitro ), SAMS, hepatotoxicity, lab-  based efficacy (choles -\nterol lowering), and clinical efficacy (vascular event reduction). \nStatins evaluated included simvastatin, rosuvastatin, pravastatin, \npitavastatin, atorvastatin, fluvastatin, and lovastatin. We reviewed \nthe evidence for SLCO1B1 , ABCG2 , CYP2C9 , CYP3A4/5 , and \nHMGCR  and applied a grading system for each piece of evi -\ndence that evaluated an association between genotype and phe -\nnotype ( Tables\xa0 S1–  S5). We found the highest levels of evidence \nfor SLCO1B1  (all statins), ABCG2  (rosuvastatin), and CYP2C9', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: What is the brand name for pitavastatin?
retrieved_docs: [Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and atorvastatin therapy. Pharmacoepidemiol Drug Saf  19, 75-81 (2010).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='an increased concentration of pitavastatin. Zhou, et al. (2013) (129) Weak', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='response to simvastatin. Arterioscler Thromb Vasc Biol  30, 1485-92 (2010).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: What are the guidelines for a phenotype of SLCO1B1 Poor Function?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *5/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*9 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*5 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*49 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*48 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*49 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*48 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*31 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*47 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*9 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*31 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*48 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*47 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*23 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*49 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*23 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*47 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*31 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has SLCO1B1 Indeterminate phenotype. What statin should I prescribe?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*3 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*2 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*11 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*4 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*10 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*6 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*12 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What are the associated drugs for a phenotype of SLCO1B1 Decreased Function?
retrieved_docs: [Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1009allele have an SLCO1B1 decreased function phenotype and \nindividuals with two no function alleles ( e.g., SLCO1B1*5/*5 ) \nhave an SLCO1B1 poor function phenotype.\nThe most common and well- studied variant in SLCO1B1 is \nc.521T>C (rs4149056), and it can be genotyped alone (e.g., poly -\nmerase chain reaction–  based single SNV assay) or multiplexed \non a variety of array-  based platforms. All SLCO1B1 genetic tests \nshould interrogate c.521T>C; however, while other less common \nvariants in this gene may have limited evidence to guide action, \nthey may also be important (SLCO1B1 Allele Definition T able \nand SLCO1B1 Allele Functionality T able6,7).ABCG2.  Unlike SLCO1B1  and CYP2C9 , there is no star allele \nnomenclature to represent ABCG2  variants at this time. \nAssignment of the predicted ABCG2 phenotype is summarized \nin Table\xa0 1. An individual carrying one normal function allele plus', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*49 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*14 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*14 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*48 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*49 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does it mean to have a phenotype of SLCO1B1 No Result?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *8/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*14 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *8/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*29 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*19 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What are statin dosage guidelines for a phenotype of SLCO1B1 Decreased Function?
retrieved_docs: [Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1013Table 2 Dosing recommendations for statins based on SLCO1B1 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nAll statins\nSLCO1B1 increased \nfunctionTypical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nSLCO1B1 normal function Typical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nAtorvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1015Phenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nSLCO1B1 poor function Increased pravastatin \nstatin exposure as \ncompared with normal \nand decreased function; \ntypical myopathy risk with \ndoses ≤40\xa0mgPrescribe ≤40 mg as a starting dose and adjust \ndoses of pravastatin based on disease-  specific \nguidelines. If patient is tolerating 40-  mg dose \nbut higher potency is needed, a higher dose \n(>40 mg) or an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins) \nor combination therapy (i.e., pravastatin plus \nnonstatin guideline-  directed medical therapy)3 \ncould be considered. Prescriber should be aware of \npossible increased risk for myopathy especially with \npravastatin doses >40\xa0mgModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='16 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S1.  EVIDENCE LINKING SLCO1B1 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References Level of Evidence Atorvastatin In vitro SLCO1B1 is the major atorvastatin uptake transporter.  The average contribution to atorvastatin uptake was SLCO1B1 > SLCO1B3 >> OATP2B1 > NTCP. Vildhede, et al. (2014) (83) Weak In vitro  SLCO1B1 rs4149056 (c.521T>C, *5) reduces atorvastatin transport activity by decreasing OATP1B1 function due to sorting errors in transporter localization Kameyama, et al. (2005) (84) Weak Clinical SLCO1B1 rs4149056 (c.521T>C) C allele is associated with an increased risk of atorvastatin-induced myopathy. Puccetti, et al. (2010) (85) Brunham, et al. (2012) (86) Santos, et al. (2012) (87) Hou, et al. (2015) (88) Hubacek, et al. (2015) (89) Mirosevic, et al. (2015) (90) Liu, et al. (2017) (91) Xiang, et al. (2018) (92) Du, et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='14 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0   FIGURE S1. PHARMACOKINETIC IMPACT OF RS4149056 GENOTYPE FOR SEVERAL STATINS.  Effect of the SLCO1B1 c.521T>C variant (rs4149056) on plasma exposure (i.e., area under the concentration-time curve) for different statins, CC vs TT. This summary figure represents a composite of single-dose data from the following references: Pasanen et al (4), Ieiri et al (18), Lee et al. (77), Niemi et al (78), Pasanen et al (79), Choi et al (80), Deng et al (17), Ho et al (81).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='recommendations generated by extrapolating evidence supporting \nthe single gene associations and assuming that they are additive, \nare provided for rosuvastatin in Table\xa0 5 and fluvastatin in \nTable\xa0 6. Because there are limited clinical or pharmacokinetic \ndata regarding these combinatorial phenotypes, pharmacotherapy \nrecommendations are classified as optional for the high-  risk \nphenotype groups (e.g., SLCO1B1 no function plus ABCG2 \nno function). In the case of fluvastatin recommendations for \nCYP2C9 poor metabolizers who also have SLCO1B1 decreased \nor poor function, we recommend prescribing an alternative agent \nrather than prescribing a lower dose based on the available dosage \nforms (no dosage form less than 20\xa0mg is available for fluvastatin).\nGeneral guidance for patients already receiving statin therapy.  The \ntherapeutic recommendations described herein predominately \napply to a new or a revision (dose or type) to statin prescription.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='18 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Du, et al. (2018) (93) Fluvastatin Clinical Presence of the SLCO1B1*14 allele is associated with enhanced lipid-lowering efficacy for fluvastatin. Couvert, et al. (2008) (115) Moderate Clinical The SLCO1B1 rs4149056 (c.521T>C) C variant is associated with decreased lipid- lowering response to fluvastatin. Couvert, et al. (2008) (115) Meyer, et al. (2015) (110) Xiang, et al. (2018) (116) Weak In vitro The uptake of fluvastatin was not influenced by SLCO1B1 rs4149056 (c.521T>C) at concentrations >1 uM Deng, et al. (2008) (117) Xiang, et al. (2020 (118) Moderate In vitro The SLCO1B1 rs4149056 (c.521T>C) C variant is associated with reduced uptake of both fluvastatin enantiomers (3R,5S-fluvastatin and 3S,5R-fluvastatin). Hirvensalo, et al. (2019) (119) Moderate Clinical Fluvastatin PK did not differ between subjects with different SLCO1B1 rs4149056 (c.521T>C) genotypes. Niemi, et al. (2006) (120) Zhou, et al.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My pharma genetic test shows that I have SLCO1B1 increased function. Does this impact any medications I take?
retrieved_docs: [Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='de novo variants are often not tested for within currently available genotyping tests, if discovered, it may be unclear how to act upon such results. Yet, rare exonic variants in SLCO1B1 have been shown to have clinical impact (e.g., methotrexate clearance) (66). Therefore, altered drug kinetics and increased risk for severe drug toxicity may still occur in the absence of a c.521 C allele, and a c.521TT genotype at rs4149056 does not necessarily imply the absence of other potentially function-altering variant(s) in SLCO1B1. Allele and variant function are available on PharmVar.org as well as CPIC’s SLCO1B1Allele Functionality Table (67, 68).  RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN EHR WITH CDS  Clinical decision support (CDS) tools integrated within electronic health records (EHRs) can help guide clinical pharmacogenetics at the point of care (69-73).  See https://cpicpgx.org/guidelines/cpic-guideline-for-statins/ for resources to support the adoption of CPIC guidelines', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='test information by providers and is available at http://www.ncbi.nlm.nih.gov/gtr/.   LINKING GENETIC VARIABILITY TO VARIABILITY IN DRUG-RELATED PHENOTYPES  SLCO1B1. Both SLCO1B1 decreased and poor function phenotypes are associated with increased exposure for most statins, with greater effects of poor function phenotypes.  Effects on exposure also vary by statin type (Figure S1). Therefore, the risk of SAMS varies based on statin type and statin dose. For simvastatin, the evidence linking SAMS to SLCO1B1 rs4149056 (c.521T>C) is of high quality, and this association has been reproduced in retrospective studies of randomized trials and clinical practice-based cohorts (Table S1). This variant is present in several SLCO1B1 star alleles including the relatively common SLCO1B1*5 and *15 alleles. Although the association of rs4149056 with myopathy varies by statin, there is evidence supporting the role of SLCO1B1 variants in the systemic clearance of all statins (3) (Table S1).  Pasanen et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1009allele have an SLCO1B1 decreased function phenotype and \nindividuals with two no function alleles ( e.g., SLCO1B1*5/*5 ) \nhave an SLCO1B1 poor function phenotype.\nThe most common and well- studied variant in SLCO1B1 is \nc.521T>C (rs4149056), and it can be genotyped alone (e.g., poly -\nmerase chain reaction–  based single SNV assay) or multiplexed \non a variety of array-  based platforms. All SLCO1B1 genetic tests \nshould interrogate c.521T>C; however, while other less common \nvariants in this gene may have limited evidence to guide action, \nthey may also be important (SLCO1B1 Allele Definition T able \nand SLCO1B1 Allele Functionality T able6,7).ABCG2.  Unlike SLCO1B1  and CYP2C9 , there is no star allele \nnomenclature to represent ABCG2  variants at this time. \nAssignment of the predicted ABCG2 phenotype is summarized \nin Table\xa0 1. An individual carrying one normal function allele plus', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020SLCO1B1 521TC: simvastatine4055When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*13 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020CYP2C9 *1/*2: siponimod7160NO action is required for this gene-drug interaction.The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects.Literature:1. Gardin A et al. Siponimod', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*43 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*14 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient takes Livalo for their high cholesterol and is complaining of muscle pain after they started taking their medication. Genetic test results show that they have SLCO1B1 decreased function. How should I adjust dosage?
retrieved_docs: [Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: My patient takes Simvastatin but is complaining of myopathy. Can you tell me the genes and protien function of those genes that could potentially cause myopathy so that I can order an appropriate pgx test for my patient? What should be the predicted phenotype function I should consider to adjust dosage?
retrieved_docs: [Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='(as a function of statin type and dose, comedications, and the pathophysiological or genetic setting). \nIf the genotype is not known early, the RNPGx considers that a polymo rphism test is potentially \nuseful  in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a \ngenetic cause [12, 13].  \n \nConclusion s \n \nProgress achieved in recent years in the field of genetics has broadened our knowledge of the \nmolecular mechanisms implicated in the therapeutic response or the toxicity of drugs widely used \nfor cardiovascular diseases. The level of evidence  for pharmacoge netic tools available today is \nsufficient for clinical applications designed to predict and anticipate VKA resistance or hemorrhagic', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 33  (20) Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun  5, 5068 (2014). (21) Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther  86, 197-203 (2009). (22) DeGorter, M.K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet  6, 400-8 (2013). (23) Bai, X. et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol Sin  40, 492-9 (2019). (24) Chu, A.Y. et al. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. Circ', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 44  (219) Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J  11, 274-86 (2011). (220) Kivisto, K.T. et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics  14, 523-5 (2004). (221) Fiegenbaum, M. et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther  78, 551-8 (2005). (222) Hu, M., Mak, V.W., Xiao, Y. & Tomlinson, B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics  14, 25-34 (2013). (223) Kolovou, G. et al. Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. Open Cardiovasc Med J  8, 12-7 (2014). (224) Elens, L. et al. Novel CYP3A4', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 36  (75) Hoffman, J.M. et al. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). J Am Med Inform Assoc  23, 796-801 (2016). (76) Pulley, J.M. et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther  92, 87-95 (2012). (77) Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther  78, 330-41 (2005). (78) Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical pharmacology and therapeutics  80, 356-66 (2006). (79) Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='29 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S5.  EVIDENCE LINKING CYP3A4/5 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced muscle symptoms. Shek, et al. (2017) (134) Liu, et al. (2017) (91)  Weak Clinical  CYP3A5*3/*3 genotype (6986A>G) is more frequent in statin-intolerant cases. Shek, et al. (2018) (162) Weak Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced liver symptoms. Shek, et al. (2017) (134) Weak Clinical When simvastatin-intolerant patients were switched to rosuvastatin, serious side effect were not observed and many of them carry CYP3A5*3/*3. Shek, et al. (2018) (162) Weak Clinical  CYP3A4 rs2740574 (G>A) G allele is associated with smaller risk of a dose decrease or switch to another drug during simvastatin and atorvastatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39%and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option:1. Avoid simvastatin doses', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 45  (237) Shin, J., Pauly, D.F., Pacanowski, M.A., Langaee, T., Frye, R.F. & Johnson, J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy  31, 942-50 (2011).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My pgx test result shows that I have possible decreased function in the gene slco1b1, what does this mean for my  zocor medication?
retrieved_docs: [Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient takes pravastatin, can poor function SLCO1B1 phenotype cause myopathy?
retrieved_docs: [Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020SLCO1B1 521TC: simvastatine4055When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore) 2015;94:e1268.6. Luzum JA et al. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. J Cardiovasc Pharmacol 2015;66:80-5.7. Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Hopewell JC et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient takes zocor, what SLCO1B1 phenotype  can cause myopathy?
retrieved_docs: [Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020SLCO1B1 521TC: simvastatine4055When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 37  (94) Ramakumari, N., Indumathi, B., Katkam, S.K. & Kutala, V.K. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J  70 Suppl 3, S120-S5 (2018). (95) Mori, D. et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet  34, 78-86 (2019). (96) Linskey, D.W. et al. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics  30, 208-11 (2020). (97) Turner, R.M. et al. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clin Pharmacol Ther  108, 287-97 (2020). (98) Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M. & Mushiroda, T. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore) 2015;94:e1268.6. Luzum JA et al. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. J Cardiovasc Pharmacol 2015;66:80-5.7. Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Hopewell JC et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='(2018). (156) Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol  54, 1609-16 (2009). (157) Khine, H., Yuet, W.C., Adams-Huet, B. & Ahmad, Z. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J  179, 1-9 (2016). (158) Floyd, J.S. et al. Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS One  14, e0218115 (2019). (159) Carr, D.F. et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther  94, 695-701 (2013). (160) Li, J.H. et al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med  4, 147-62 (2014). (161) Peyser, B. et al. Effects of Delivering SLCO1B1 Pharmacogenetic Information in', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simple myalgia to potentially lethal rhabdomyolysis. This toxicity led to the removal of cerivastatin \nfrom the French market in 2003. The relationship between statin pharmacokinetics, the presence of \nSLCO1B1  polymorphism(s) and the occurrence of muscle toxicity has been demonstrated.  \n \n \nBasic concepts and indications for pharmacogenetic testing: statins and SLCO1B1  genotyping  \n \nSLCO1B1  polymorphism  \n \nSeveral factors such as the activity level of the transporter OATP1B1 affect exposure to statins. \nOATP1B1 is coded for by the SLCO1B1  gene on chromosome 12. It is expressed on the basolateral \npole of hepatocytes where it is involved in sodium -dependent cap ture of diverse drugs (statins, \nrepaglinide, methotrexate) and endogenous substanc es such as biliary acids, estrad iol, \nprostaglandins, thromboxane , leukotrienes  or thyroxin.  \nActivation of the OATP1B1 transporter is genetically determined by SLCO1B1', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 38  (111) Prado, Y., Saavedra, N., Zambrano, T., Lagos, J., Rosales, A. & Salazar, L.A. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci  16, 20609-19 (2015). (112) Mladenovska, K. et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie  72, 288-95 (2017). (113) de Keyser, C.E. et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics  24, 43-51 (2014). (114) Kadam, P., Ashavaid, T.F., Ponde, C.K. & Rajani, R.M. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther  41, 329-33 (2016). (115) Couvert, P. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What phenotype function causes increased myopathy risk for lovastatin?
retrieved_docs: [Document(page_content='rosuvastatin levels (AUC and Cmax) may be doubled in individuals with poor function phenotypes (21). Based on the observed increase in exposure, the risk for myopathy would also be expected to be increased (22). Nonetheless, there is only a single study directly assessing myopathy due to rosuvastatin use in individuals with decreased or poor function phenotypes which did not show any significant effect on myopathy (23). However, for efficacy, the JUPITER Trial showed an increase in lipid lowering effects of rosuvastatin in individuals with decreased and poor function phenotypes (24).  Dosing based on genotype for rosuvastatin must necessarily include other considerations such as liver or renal function and ancestry (Table 3).  The higher levels of rosuvastatin observed in individuals of Asian ancestry have been attributed', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='CYP3A5 protein). While neither variant has been shown to predict myopathy while on atorvastatin, Wilke et al. describe an association for these variants with the severity of muscle damage in a small cohort of 68 patients who reported myalgias while taking  atorvastatin (27). Although significant, the effect size was modest. For patients with myalgias on atorvastatin, the median CK level was 321 units/L in carriers of the CYP3A4*1B allele, vs 246 units/L in non-carriers (adjusted p = 0.059), and the median CK level was 318 units/L in carriers of the CYP3A5*3 allele, vs 246 units/L in non-carriers (adjusted p = 0.010).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='or pharmacodynamics of other statins are not affected. To date, studies have focused on two alleles, CYP2C9*2 (decreased function) and CYP2C9*3 (no function). Hirvensalo et al. showed that for fluvastatin the AUC was 25% and 75% greater per copy of the CYP2C9*2 and CYP2C9*3 variant allele, respectively. Additionally, CYP2C9*2 and CYP2C9*3 alleles are associated with increased risk of fluvastatin-induced adverse effects, including liver toxicity and SAMS. However, the evidence supporting increased risk of myopathy in carriers of decreased or poor function alleles of CYP2C9 is of moderate quality and mainly based on the pharmacokinetic evidence. Genetic variation in CYP2C9 has not been associated with fluvastatin lipid-lowering response.   CYP3A4 and CYP3A5.  To date, studies have focused on two alleles, CYP3A4*1B (a promoter variant) and CYP3A5*3 (harboring a common intronic variant causing a splice defect which leads to truncated inactive CYP3A5 protein). While neither variant has', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39%and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option:1. Avoid simvastatin doses', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='29 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S5.  EVIDENCE LINKING CYP3A4/5 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced muscle symptoms. Shek, et al. (2017) (134) Liu, et al. (2017) (91)  Weak Clinical  CYP3A5*3/*3 genotype (6986A>G) is more frequent in statin-intolerant cases. Shek, et al. (2018) (162) Weak Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced liver symptoms. Shek, et al. (2017) (134) Weak Clinical When simvastatin-intolerant patients were switched to rosuvastatin, serious side effect were not observed and many of them carry CYP3A5*3/*3. Shek, et al. (2018) (162) Weak Clinical  CYP3A4 rs2740574 (G>A) G allele is associated with smaller risk of a dose decrease or switch to another drug during simvastatin and atorvastatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='26 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Kirschheiner, et al. (2003) (192) Hirvensalo, et al. (2019) (119) Clinical CYP2C9*2 or *3 allele is associated with greater odds of developing fluvastatin-induced adverse effects (liver and muscle toxicity). Mirosevic, et al. (2013) (186) Moderate Unknown Statins, CYP2C9 genotypes are not significantly associated with muscle tox or lipid response to statins (simvastatin, fluvastatin, rosuvastatin). Zuccaro, et al. (2007) (193) Weak Clinical A case with liver cirrhosis who experienced fluvastatin-induced fatal rhabdomyolysis. This patient had been treated with simvastatin (20 mg/day) for coronary artery disease and was switched to fluvastatin (20 mg/day) 10 days before admission. Baek, et al. (2011) (194) Weak Clinical CYP2C9*3 is not associated with LDL response to rosuvastatin. Bailey, et al. (2010) (148) Moderate  Clinical CYP2C9*3 allele is associated with an increased concentration of pitavastatin. Zhou,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore) 2015;94:e1268.6. Luzum JA et al. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. J Cardiovasc Pharmacol 2015;66:80-5.7. Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Hopewell JC et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='leads to reduced simvastatin transport to the liver, which increases the simvastatin plasma concentration and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: My patient has increased fucntion for the SLCO1B1 gene,  do I need to adjust his statin dosage?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient is on atorvastatin and seems to be developing atorvastatin induced myopathy. I have ordered a PGx test and results show that she has decreased function in slco1b1, what are CPIC recommendations?
retrieved_docs: [Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='3 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE OF CONTENTS CPIC Updates.................................................................................................................................. 4 Literature Review ............................................................................................................................ 4 Available Genetic Test Options ...................................................................................................... 5 Linking genetic variability to variability in drug-related phenotypes ............................................ 6 Levels of evidence .......................................................................................................................... 9 Strength of dosing recommendations ............................................................................................ 10 Other Considerations', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 45  (237) Shin, J., Pauly, D.F., Pacanowski, M.A., Langaee, T., Frye, R.F. & Johnson, J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy  31, 942-50 (2011).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 37  (94) Ramakumari, N., Indumathi, B., Katkam, S.K. & Kutala, V.K. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J  70 Suppl 3, S120-S5 (2018). (95) Mori, D. et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet  34, 78-86 (2019). (96) Linskey, D.W. et al. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics  30, 208-11 (2020). (97) Turner, R.M. et al. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clin Pharmacol Ther  108, 287-97 (2020). (98) Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M. & Mushiroda, T. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 33  (20) Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun  5, 5068 (2014). (21) Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther  86, 197-203 (2009). (22) DeGorter, M.K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet  6, 400-8 (2013). (23) Bai, X. et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol Sin  40, 492-9 (2019). (24) Chu, A.Y. et al. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. Circ', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='1 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Supplemental Material  The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms Authors:  *Rhonda M. Cooper-DeHoff1,2,  *Mikko Niemi3,4,5, Laura B. Ramsey6,7, Jasmine A. Luzum8, E. Katriina Tarkiainen3,4,5, Robert J. Straka9, Li Gong10, Sony Tuteja11, Russell A. Wilke12, Mia Wadelius13, Eric A. Larson12, Dan M. Roden14,15, Teri E. Klein10, Sook Wah Yee16, Ronald M. Krauss17, Richard M. Turner18, Latha Palaniappan19, Andrea Gaedigk20, Kathleen M. Giacomini16, Kelly E. Caudle22, Deepak Voora23  1Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA 2Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA 3Department of', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 36  (75) Hoffman, J.M. et al. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). J Am Med Inform Assoc  23, 796-801 (2016). (76) Pulley, J.M. et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther  92, 87-95 (2012). (77) Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther  78, 330-41 (2005). (78) Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical pharmacology and therapeutics  80, 356-66 (2006). (79) Pasanen, M.K., Fredrikson, H., Neuvonen, P.J. & Niemi, M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='24 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Clinical ABCG2 rs2231142 (c.421C>A) is significantly associated with atorvastatin exposure. Keskitalo, et al. (2009) (21) DeGorter, et al. (2013) (22) Birmingham, et al. (2015) (101) Tsamandouras, et al. (2017) (180) Lee, et al. (2019) (106) Weak', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are the implications of having a SLCO1B1 increased function phenotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

